OTTAWA, Oct. 29, 2021 (GLOBE NEWSWIRE) — HEXO Corp. (TSX: HEXO; NASDAQ: HEXO) (“HEXO” or the “Company”) today reported its financial results for the fourth quarter (“Q4’21”) and fiscal year ended July 31, 2021 (“F’21”). All amounts are expressed in Canadian dollars unless otherwise noted.
“I am honoured and humbled to join the team as HEXO’s President & CEO,” said Scott Cooper. “I look forward to continuing to build on HEXO’s strong foundation with an immediate priority of continuing to integrate our recent acquisitions and reviewing our financial position, with the ultimate goal of driving growth and profitability through the commercialization of cannabis consumer packaged goods products.”
“As we review our last fiscal year, I would like to highlight some key achievements. Last fiscal, HEXO achieved its highest net revenue in the Company’s history, leads the Canadian cannabis market in four categories and completed three acquisitions, including the transformative Redecan acquisition, propelling the Company to the number one market share position in Canadian adult-use recreational cannabis sales,” commented Cooper.
Business Update
M&A
Key Highlights to July 31, 2021
Subsequent Events
Operations
Key Highlights to July 31, 2021
Subsequent Events
Canadian cannabis market
Key Highlights to July 31, 2021
Maintained leading market position relative to peers as market share continues to diversify.
HEXO USA
Key Highlights to July 31, 2021
Subsequent Events
Financial Update
| In 000’s | For the three months ended | For the twelve months ended |
||||||||
| Income Statement Snapshot | July 31, 2021 |
April 30, 2021 |
July 31, 2020 |
July 31, 2021 |
July 31, 2020 |
|||||
| $ | $ | $ | $ | $ | ||||||
| Revenue from sale of goods | 53,022 | 33,082 | 36,140 | 173,081 | 110,149 | |||||
| Excise taxes | (14,365 | ) | (10,482 | ) | (9,082 | ) | (49,583 | ) | (29,598 | ) |
| Net revenue from sale of goods | 38,657 | 22,600 | 27,058 | 123,498 | 80,551 | |||||
| Ancillary revenue | 103 | 60 | 87 | 271 | 233 | |||||
| Total revenue | 38,760 | 22,660 | 27,145 | 123,769 | 80,784 | |||||
| Gross profit before adjustments2 | 7,988 | 5,006 | 8,104 | 34,175 | 26,953 | |||||
| Gross profit/(loss) before fair value adjustments | 1,499 | 4,379 | (36,012 | ) | 29,066 | (46,421 | ) | |||
| Gross profit/(loss)2 | 3,234 | 8,816 | (34,690 | ) | 48,798 | (57,975 | ) | |||
| Operating expenses | (63,116 | ) | (24,906 | ) | (71,509 | ) | (134,293 | ) | (418,576 | ) |
| Loss from operations | (59,882 | ) | (16,090 | ) | (106,199 | ) | (85,495 | ) | (476,551 | ) |
| Other expenses and losses | (9,630 | ) | (4,621 | ) | (63,333 | ) | (29,664 | ) | (75,961 | ) |
| Loss and comprehensive loss before tax | (69,512 | ) | (20,711 | ) | (169,532 | ) | (115,159 | ) | (552,512 | ) |
| Current and deferred tax recovery | 397 | – | – | 397 | 6,023 | |||||
| Other comprehensive income | 1,156 | 3 | – | 1,152 | – | |||||
| Total Net loss and comprehensive loss | (67,959 | ) | (20,708 | ) | (169,532 | ) | (113,610 | ) | (546,489 | ) |
| 1 | The Company has adjusted the presentation of gross profit before fair value adjustments by removing inventory and biological asset write offs and impairment losses. |
| 2 | See section ‘Cost of Sales, Excise Taxes and Fair Value Adjustments’ for reconciliation of gross profits |
Operating Expenses
| In 000’s | For the three months ended |
For the years ended |
|||||
| July 31, 2021 |
April 30, 2021 |
July 31, 2020 |
July 31, 2021 |
July 31, 2020 |
|||
| $ | $ | $ | $ | $ | |||
| Selling, general and administration1 | 19,160 | 11,178 | 12,436 | 54,543 | 52,793 | ||
| Marketing and promotion | 3,665 | 2,452 | 2,375 | 10,348 | 12,474 | ||
| Share-based compensation | 827 | 2,715 | 4,373 | 11,731 | 25,790 | ||
| Research and development | 934 | 730 | 677 | 3,835 | 4,639 | ||
| Depreciation of property, plant and equipment | 1,728 | 1,612 | 1,179 | 6,097 | 6,072 | ||
| Amortization of intangible assets | 1,002 | 371 | 249 | 2,050 | 3,939 | ||
| Restructuring costs | 1,562 | 336 | (79 | ) | 3,283 | 4,767 | |
| Impairment of property, plant and equipment | 19,350 | 16 | 46,414 | 20,230 | 79,418 | ||
| Impairment of intangible assets | – | – | 2,000 | – | 108,189 | ||
| Impairment of goodwill | – | – | – | – | 111,877 | ||
| Realization of onerous contract | – | – | 1,763 | – | 4,763 | ||
| Disposal of long-lived assets | – | – | 122 | 1,294 | 3,855 | ||
| Loss/(gain) on disposal of property, plant and equipment | 19 | (19 | ) | – | 64 | – | |
| Acquisition transaction costs | 14,869 | 1,871 | – | 17,174 | – | ||
| Health Canada Recovery Fee’s1 | – | 3,644 | – | 3,644 | – | ||
| Total | 63,116 | 24,906 | 71,509 | 134,293 | 418,576 | ||
| 1 | The Company has adjusted the presentation of the Selling, General and Administrative expenses to breakdown the Health Canada Recovery Fee’s for ease of user review and identification. This presentation differs from that of the Company’s interim financial statement for the year ended July 31, 2021. |
Other Matters
Gross margins
Quarter-over-quarter, the Company’s total gross margin declined to 20% from 22% in Q3’21. Net adult-use revenue (exclusive of beverages) gross margin declined to 12% from 28% due to; increases to sales in higher excise tax burdened markets, decreases to average selling prices, and the crystallization of fair value adjustments upon the business acquisition of Zenabis.
Normalizing for the impact of the crystallization, the Company’s total gross margin would improve to 26% in Q4’21. Strong margined international sales grew significantly in period to net revenues of $6.8 million and a gross margin contribution of 65%. Wholesales were also impacted by the crystallization of fair value adjustments on the purchase price accounting of Zenabis, normalized for this, margins would otherwise have been 35% versus reported gross margin of (65%).
Going Concern & the Senior Secured Convertible Note
The Company acknowledges the ongoing concern with its senior secured convertible notes issued on May 27, 2021. The Company has maintained a positive relationship with the holder, with the holder having negotiated and agreed to two amendments favorable to the Company. While there exists a risk that significant cash outflows may be required over the next twelve months under the terms of the Senior Secured Convertible Note, the Company has been working with the Holder to renegotiate the terms of the Senior Secured Convertible Note.
The Company has sufficient funding for ongoing working capital requirements, however, current funds on hand, combined with operational cash flows, are not sufficient to also support funding potential cash requirements under the Senior Secured Convertible Note, investments required to continue to develop cultivation and distribution infrastructure, and the future growth plans of the Company. Management is exploring several options to secure the necessary financing, which could include the issuance of new public or private equity or debt instruments, supplemented with operating cash inflows from operations.
Nevertheless, there is risk that certain sources of additional future funding will not be available to the Company or will be available on terms which are acceptable to management. In the meantime, Management continues to monitor and manage its cash flow in relation to its strategic growth objectives and working capital requirements.
Non-IFRS Measures
In this press release, reference is made to gross profit before adjustment, profit/margin before fair value adjustments, adjusted gross profit/margin, adjusted EBITDA, and revenue per gram equivalent which are not measures of financial performance under International Financial Reporting Standards (IFRS). These metrics and measures are not recognized measures under IFRS, do not have meanings prescribed under IFRS, and are unlikely to be comparable to similar measures presented by other companies. These measures are provided as information complementary to those IFRS measures by providing a further understanding of our operating results from the perspective of management. As such, these measures should not be considered in isolation or in lieu of a review of our financial information reported under IFRS. Definitions and reconciliations for all terms above can be found in the Company’s Management’s Discussion and Analysis for the fiscal year ended July 31, 2021, filed under the Company’s profile on SEDAR at www.sedar.com and EDGAR at www.sec.gov respectively
Conference Call
The Company will hold a conference call, October 29, 2021 to discuss these results. Scott Cooper, President & CEO, and Trent MacDonald, CFO, will host the call starting at 8:30 a.m. Eastern. Analysts’ question and answer period will follow management’s presentation.
Date: October 29, 2021
Time: 8:30 a.m. ET
Webcast: https://events.q4inc.com/attendee/987736433
For previous quarterly results and recent press releases, see hexocorp.com.
About HEXO Corp
HEXO is an award-winning licensed producer of innovative products for the global cannabis market. HEXO serves the Canadian recreational market with a brand portfolio including HEXO, Redecan, UP Cannabis, Namaste Original Stash, 48North, Trail Mix, Bake Sale, REUP and Latitude brands, and the medical market in Canada, Israel and Malta. The Company also serves the Colorado market through its Powered by HEXO® strategy and Truss CBD USA, a joint venture with Molson-Coors. With the completion of HEXO’s recent acquisitions of Redecan and 48North, HEXO is a leading cannabis products company in Canada by recreational market share. For more information, please visit www.HEXOcorp.com.
Forward-Looking Statements
This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. Forward-looking statements in this press release include but are not limited to the Company’s statements with respect to management’s belief that certain expenses included in operating expenses are non-recurring and related to significant changes in market conditions and the refocus of its operations on becoming Adjusted EBITDA positive.
A more complete discussion of the risks and uncertainties facing the Company appears in the Company’s Annual Information Form and other continuous disclosure filings, which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.
Investor Relations:
invest@hexo.com
www.hexocorp.com
Media Relations:
(819) 317-0526
media@hexo.com
1 Estimated personal emissions based on the average Canadian’s emissions from heating and powering their homes, driving and food consumption.
- Leading efficient care management for the elderly with unimpeded smartcare https://img.hankyung.com/pdsdata/pr.hankyung.com/uploads/2024/11/image01-1.png SEOUL, South Korea, Nov.…
- Attruby is the first and only approved product with aspecifying near-complete stabilization…
PALO ALTO, Calif., Nov. 22, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…
Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB:…
3,250 InsuJet Starter Packs Being Delivered to Pharmacies Across CanadaToronto, Ontario--(Newsfile Corp. - November 22,…